Results 11 to 20 of about 3,679 (147)

Efficacy and Safety of Adjunctive Perampanel in Young Children (7-46 Months) With Drug-Resistant Epilepsy: A Real-World Study. [PDF]

CNS Neurosci Ther
This real‐world study evaluates adjunctive perampanel (PER) in young children (7–46 months) with drug‐resistant epilepsy. Results show clinically meaningful efficacy, with responder rates of up to 50% in certain syndromes. PER demonstrates a favorable safety profile, supporting its role as an effective treatment option in this age group.
Zeng Q, Xia X, Zheng H, Yang L, Jiang L, Hu Y.   +5 more
europepmc   +2 more sources

Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature

Frontiers in Neurology, 2021
Introduction: Progressive myoclonic epilepsies (PMEs) are a heterogenous group of genetic diseases presenting with epilepsy, cognitive impairment, and severe action myoclonus, which can severely affect daily life activities and independent walking ...
Giovanni Assenza, Cristofaro Nocerino, Mario Tombini, Giancarlo Di Gennaro, Alfredo D'Aniello, Alberto Verrotti, Alfonso Marrelli, Lorenzo Ricci, Jacopo Lanzone, Vincenzo Di Lazzaro, Leonilda Bilo, Antonietta Coppola   +11 more
doaj   +1 more source

Infection-Induced Elevated Plasma Perampanel in a Patient with Hemimegalencephaly

Case Reports in Pediatrics, 2022
Perampanel is a noncompetitive, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor antagonist. Herein, we report a case of increased perampanel plasma concentration and impaired consciousness triggered by an infection.
Yuya Kinoshita, Hiroe Ueno, Hirofumi Kurata, Chizuru Ikeda, Erika Hori, Takumi Okada, Tomoyuki Shimazu, Isao Fujii, Makoto Matsukura, Hoseki Imamura   +9 more
doaj   +1 more source

A nomogram to predict the treatment benefit of perampanel in drug-resistant epilepsy patients

Frontiers in Neurology, 2023
ObjectiveThe objective of this study was to identify the factors that affect the efficacy of added perampanel for the treatment of drug-resistant epilepsy (DRE), and to develop a reliable nomogram to predict the benefit of this addition.MethodsA ...
Chaofeng Zhu, Juan Li, Dazhu Wei, Luyan Wu, Yuying Zhang, Huapin Huang, Huapin Huang, Huapin Huang, Wanhui Lin, Wanhui Lin   +9 more
doaj   +1 more source

Perampanel attenuates oxidative stress and pyroptosis following subarachnoid hemorrhage via the SIRT3/FOXO3α pathway

Scientific Reports, 2023
Subarachnoid hemorrhage (SAH) occurs most commonly after rupture of an aneurysm, resulting in high disability and mortality due to the absence of effective therapy.
Hongqiao Yang, Changgeng Ding, Ming Cheng, Zhengwei Sheng, Lei Chen, Junhui Chen, Yuhai Wang   +6 more
doaj   +1 more source

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India

Epilepsia Open, 2021
Objective This post hoc analysis assessed the efficacy and safety of adjunctive perampanel in patients (aged ≥ 12 years) with focal seizures (FS), with/without focal to bilateral tonic‐clonic seizures (FBTCS), or generalized tonic‐clonic seizures (GTCS ...
Man M. Mehndiratta, Manoj Gulhane, Shaik A. Jabeen, Anna Patten, Amitabh Dash, Manoj Malhotra   +5 more
doaj   +1 more source

Perampanel Affects Up-Stream Regulatory Signaling Pathways of GluA1 Phosphorylation in Normal and Epileptic Rats

Frontiers in Cellular Neuroscience, 2019
To elucidate the pharmacological properties of perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile, a novel non-competitive antagonist of AMPA receptor], we investigated its effects on the up-stream regulatory pathways of ...
Ji-Eun Kim, Ji-Eun Kim, Hui-Chul Choi, Hui-Chul Choi, Hong-Ki Song, Hong-Ki Song, Tae-Cheon Kang, Tae-Cheon Kang   +7 more
doaj   +1 more source

EARLY ONSET AGGRESSIVE BEHAVIOR INDUCED BY PERAMPANEL IN THE TREATMENT OF CHRONIC INSOMNIA: A CASE REPORT

European Psychiatry, 2023
Introduction Chronic insomnia, resistant to different treatments (pharmacological, sleep hygiene and cognitive-behavioral therapy) remains one of the greatest challenges in our daily practice as psychiatrists.
I. Esteban-Avendaño, J. Torres Cortés, J. Padín Calo   +2 more
doaj   +1 more source

BUDGET IMPACT ANALYSIS OF PERAMPANEL FOR ADJUNCTIVE TREATMENT IN EPILEPSY PATIENTS 12 YEARS OF AGE AND OLDER FOR PARTIAL ONSET SEIZURES WITH OR WITHOUT SECONDARY GENERALIZATION AND PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN THE RUSSIAN FEDERATION

Фармакоэкономика, 2016
Objectives. To assess the incremental budget impact (BI) of using of utilizing perampanel to treat partial-onset seizures (POS) and primary generalized tonic-clonic seizures (PGTCS) in patients who are 12 years of age and older in Russia.Methods.
V. R. Mkrtchyan, A. M. Sergeev, K. I. Pochigaeva, I. A. Shpak   +3 more
doaj   +1 more source

Efficacy and safety of perampanel monotherapy in Chinese patients with focal‐onset seizures: A single‐center, prospective, real‐world observational study

Epilepsia Open, 2023
Objective Efficacy and safety of perampanel monotherapy for treating focal‐onset seizures (FOS) has been barely studied in China. This observational study aimed to evaluate the efficacy and safety of perampanel monotherapy in treating Chinese patients ...
Haiyan Ma, Haitao Zhu, Fangqing Chen, Yiqing Yang, Xuefeng Qu, Honghao Xu, Lu Yang, Rui Zhang   +7 more
doaj   +1 more source